TNFRSF9 and neoplasm: Our data show that α4-1BB monotherapy exhibited a therapeutic effect against CT-26 tumors which has also been observed in several other tumor models and can be attributed to the direct stimulation of 4-1BB on effector cells (11) and blocking of the reverse signaling via 4-1BBL (27).